China SXT Pharmaceuticals Inc (NASDAQ:SXTC) — Market Cap & Net Worth
Market Cap & Net Worth: China SXT Pharmaceuticals Inc (SXTC)
China SXT Pharmaceuticals Inc (NASDAQ:SXTC) has a market capitalization of $1.20 Million ($1.20 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30592 globally and #6221 in its home market, demonstrating a 5.83% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China SXT Pharmaceuticals Inc's stock price $2.36 by its total outstanding shares 533976 (533.98K). Also see China SXT Pharmaceuticals Inc total assets for a full breakdown of the balance sheet.
China SXT Pharmaceuticals Inc Market Cap History: 2019 to 2026
China SXT Pharmaceuticals Inc's market capitalization history from 2019 to 2026. Data shows change from $43.79 Million to $1.26 Million (-51.00% CAGR). Also see China SXT Pharmaceuticals Inc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
China SXT Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #902 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #2862 of 3165 |
Weight: China SXT Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
China SXT Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China SXT Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check SXTC stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
1.17x
China SXT Pharmaceuticals Inc's market cap is 1.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $43.79 Million | $7.01 Million | $1.54 Million | 6.24x | 28.45x |
| 2020 | $17.57 Million | $5.16 Million | -$10.29 Million | 3.40x | N/A |
| 2021 | $8.68 Million | $4.78 Million | -$2.75 Million | 1.82x | N/A |
| 2022 | $7.24 Million | $2.60 Million | -$5.74 Million | 2.78x | N/A |
| 2023 | $2.12 Million | $1.97 Million | -$5.93 Million | 1.08x | N/A |
| 2024 | $271.31K | $1.93 Million | -$3.10 Million | 0.14x | N/A |
| 2025 | $854.36K | $1.74 Million | -$3.30 Million | 0.49x | N/A |
| 2026 | $1.26 Million | $1.07 Million | -$6.21 Million | 1.17x | N/A |
Competitor Companies of SXTC by Market Capitalization
Companies near China SXT Pharmaceuticals Inc in the global market cap rankings as of September 17, 2026. Review SXTC goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to China SXT Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
China SXT Pharmaceuticals Inc Historical Marketcap From 2019 to 2026
Between 2019 and today, China SXT Pharmaceuticals Inc's market cap moved from $43.79 Million to $ 1.26 Million, with a yearly change of -51.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.26 Million | +47.50% |
| 2025 | $854.36K | +214.90% |
| 2024 | $271.31K | -87.20% |
| 2023 | $2.12 Million | -70.70% |
| 2022 | $7.24 Million | -16.62% |
| 2021 | $8.68 Million | -50.61% |
| 2020 | $17.57 Million | -59.88% |
| 2019 | $43.79 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of China SXT Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.20 Million USD |
| MoneyControl | $1.20 Million USD |
| MarketWatch | $1.20 Million USD |
| marketcap.company | $1.20 Million USD |
| Reuters | $1.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo,… Read more